Oragenics Initiates Phase 2a Trial for ONP-002 in Concussion Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy OGEN?
Source: NASDAQ.COM
- Trial Launch: Oragenics Inc. announced the dosing of the first patient in the Phase 2a trial for ONP-002, its candidate for treating concussions and mild traumatic brain injury, marking a significant step in a field lacking approved pharmacological treatments.
- Drug Characteristics: ONP-002 is a first-in-class intranasal neurosteroid designed to reduce neuroinflammation, oxidative stress, and edema in the brain, developed using Oragenics' proprietary dry powder spray technology, with promising results from earlier studies enhancing its market potential.
- Trial Design: The Phase 2a trial is a randomized, placebo-controlled study that plans to administer ONP-002 to 40 patients within 12 hours of a concussion, with safety and tolerability evaluated through follow-up visits and neurocognitive testing.
- Future Plans: The company expects to file an investigational new drug (IND) application by the fourth quarter of 2026, after which Phase 2b will be initiated, indicating its long-term strategic focus on brain injury treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGEN
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oragenics Reports Progress in ONP-002 Clinical Trial for mTBI
- Clinical Trial Progress: Oragenics has reported that two patients have been enrolled and eight doses of ONP-002 have been administered in its Phase IIa clinical trial for mild traumatic brain injury, marking a significant advancement in the program.
- Trial Design and Enrollment: The study is designed to enroll 40 patients at Mackay Base Hospital in Queensland, Australia, with participants receiving their first dose within 12 hours of concussion and continuing treatment for up to 30 days.
- Market Need and Potential: With an estimated 69 million cases of traumatic brain injury globally each year and no FDA-approved pharmacological treatments available, ONP-002 could become the first pharmacological standard of care in a market projected to exceed $9 billion by 2030 if successful.
- Company Outlook and Strategy: Oragenics' CEO noted that the early enrollment momentum reflects strong site readiness and the significant unmet need in concussion care, with plans for U.S. Phase IIb studies pending FDA approval of an Investigational New Drug application.
See More
Oragenics Initiates Phase 2a Trial for ONP-002 in Concussion Treatment
- Trial Launch: Oragenics Inc. announced the dosing of the first patient in the Phase 2a trial for ONP-002, its candidate for treating concussions and mild traumatic brain injury, marking a significant step in a field lacking approved pharmacological treatments.
- Drug Characteristics: ONP-002 is a first-in-class intranasal neurosteroid designed to reduce neuroinflammation, oxidative stress, and edema in the brain, developed using Oragenics' proprietary dry powder spray technology, with promising results from earlier studies enhancing its market potential.
- Trial Design: The Phase 2a trial is a randomized, placebo-controlled study that plans to administer ONP-002 to 40 patients within 12 hours of a concussion, with safety and tolerability evaluated through follow-up visits and neurocognitive testing.
- Future Plans: The company expects to file an investigational new drug (IND) application by the fourth quarter of 2026, after which Phase 2b will be initiated, indicating its long-term strategic focus on brain injury treatment.
See More
Oragenics Initiates ONP-002 Clinical Trial for Concussion Treatment
- Trial Activation: Oragenics activated its Phase IIa clinical trial for ONP-002 at Mackay Hospital in Australia on March 31, 2026, with the first patient dosed within days, indicating strong enrollment velocity and significant unmet medical need.
- Market Potential: If approved by the FDA, ONP-002 would be the first pharmacological treatment for concussion, addressing a market with an estimated 69 million individuals sustaining traumatic brain injuries globally each year, projected to exceed $9 billion by 2030.
- Innovative Drug Mechanism: ONP-002 is a first-in-class intranasal neurosteroid designed to target the underlying biology of brain injury by reducing neuroinflammation, oxidative stress, and cerebral edema, potentially transforming concussion care from symptom management to active intervention.
- Future Development Plans: Oragenics aims to submit an investigational new drug application to the FDA in Q4 2026, paving the way for subsequent Phase IIb trials in the U.S., showcasing its potential applications across various neurological conditions.
See More
Oragenics Releases Audit Opinion on Going Concern
- Audit Opinion Disclosure: Oragenics disclosed in its 2025 Annual Report that its independent auditor provided an unqualified opinion on its financial statements, yet included an explanatory paragraph regarding the company's ability to continue as a going concern, indicating financial uncertainty that may impact investor confidence.
- Financial Reporting Compliance: This announcement complies with NYSE American LLC Company Guide Section 610(b), emphasizing the company's commitment to financial transparency, even though there were no changes to the financial statements or the Annual Report.
- Clinical Development Progress: Oragenics' lead candidate, ONP-002, is in Phase IIa clinical development aimed at treating concussions and mild traumatic brain injuries affecting approximately 69 million people annually, showcasing the company's potential in the neuropharmaceutical sector.
- Future Outlook: The company is exploring ways to broaden its CNS pipeline strategy through both internal development and strategic business development, demonstrating a commitment to innovation and market expansion despite facing financial challenges.
See More
Oragenics Secures Clinical Trial Approval in Australia
- Clinical Trial Approval: Oragenics has received final approval from the Human Research Ethics Committee in Australia to commence its Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (mTBI), marking a significant advancement in developing the first pharmacological treatment for brain injuries.
- Significant Market Potential: The global market for mild traumatic brain injuries is projected to exceed $9 billion by 2030, and if approved by the FDA, ONP-002 would become the first pharmacological standard of care, addressing the needs of millions of patients currently without effective treatment options.
- Innovative Drug Mechanism: ONP-002 is designed as a first-in-class neurosteroid that targets the underlying biological mechanisms of brain injury by reducing neuroinflammation and oxidative stress, representing a potential paradigm shift from mere symptom management to active neurological intervention.
- Rigorous Trial Design: The Phase IIa clinical trial will enroll 40 patients to assess the drug's safety and tolerability, with data readout expected by the end of 2026; successful results will support further investigational new drug applications in the U.S.
See More
Oragenics Advances ONP-002 Clinical Trials for Concussion Treatment
- Clinical Trial Readiness: Oragenics has completed preparations for clinical trial sites in Australia, with the first patient dosing for ONP-002 expected to commence in 2026, marking a significant advancement in the field of brain therapeutics and potentially becoming the first pharmacological treatment for concussions.
- Significant Market Potential: The unique intranasal delivery system of ONP-002 is designed to rapidly deliver medication to the brain, targeting the approximately 1.7 to 3.8 million Americans who suffer from traumatic brain injuries annually, and if approved, it will enter a global concussion market projected to reach $9 billion by 2030.
- Strong Financial Backing: The company raised $16.5 million through the issuance of Series H convertible preferred stock and warrants, ensuring funding for the clinical development and operations of ONP-002, while a clean balance sheet with zero debt provides ample runway for future trials.
- Strategic Partnerships and Innovation: Oragenics has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for optimizing drug discovery, which may facilitate the expansion of its molecular portfolio and enhance the company's competitive edge in the neuroscience sector.
See More
Oragenics Reports Progress in ONP-002 Clinical Trial for mTBI
- Clinical Trial Progress: Oragenics has reported that two patients have been enrolled and eight doses of ONP-002 have been administered in its Phase IIa clinical trial for mild traumatic brain injury, marking a significant advancement in the program.
- Trial Design and Enrollment: The study is designed to enroll 40 patients at Mackay Base Hospital in Queensland, Australia, with participants receiving their first dose within 12 hours of concussion and continuing treatment for up to 30 days.
- Market Need and Potential: With an estimated 69 million cases of traumatic brain injury globally each year and no FDA-approved pharmacological treatments available, ONP-002 could become the first pharmacological standard of care in a market projected to exceed $9 billion by 2030 if successful.
- Company Outlook and Strategy: Oragenics' CEO noted that the early enrollment momentum reflects strong site readiness and the significant unmet need in concussion care, with plans for U.S. Phase IIb studies pending FDA approval of an Investigational New Drug application.
See More
Oragenics Initiates Phase 2a Trial for ONP-002 in Concussion Treatment
- Trial Launch: Oragenics Inc. announced the dosing of the first patient in the Phase 2a trial for ONP-002, its candidate for treating concussions and mild traumatic brain injury, marking a significant step in a field lacking approved pharmacological treatments.
- Drug Characteristics: ONP-002 is a first-in-class intranasal neurosteroid designed to reduce neuroinflammation, oxidative stress, and edema in the brain, developed using Oragenics' proprietary dry powder spray technology, with promising results from earlier studies enhancing its market potential.
- Trial Design: The Phase 2a trial is a randomized, placebo-controlled study that plans to administer ONP-002 to 40 patients within 12 hours of a concussion, with safety and tolerability evaluated through follow-up visits and neurocognitive testing.
- Future Plans: The company expects to file an investigational new drug (IND) application by the fourth quarter of 2026, after which Phase 2b will be initiated, indicating its long-term strategic focus on brain injury treatment.
See More
Oragenics Initiates ONP-002 Clinical Trial for Concussion Treatment
- Trial Activation: Oragenics activated its Phase IIa clinical trial for ONP-002 at Mackay Hospital in Australia on March 31, 2026, with the first patient dosed within days, indicating strong enrollment velocity and significant unmet medical need.
- Market Potential: If approved by the FDA, ONP-002 would be the first pharmacological treatment for concussion, addressing a market with an estimated 69 million individuals sustaining traumatic brain injuries globally each year, projected to exceed $9 billion by 2030.
- Innovative Drug Mechanism: ONP-002 is a first-in-class intranasal neurosteroid designed to target the underlying biology of brain injury by reducing neuroinflammation, oxidative stress, and cerebral edema, potentially transforming concussion care from symptom management to active intervention.
- Future Development Plans: Oragenics aims to submit an investigational new drug application to the FDA in Q4 2026, paving the way for subsequent Phase IIb trials in the U.S., showcasing its potential applications across various neurological conditions.
See More
Oragenics Releases Audit Opinion on Going Concern
- Audit Opinion Disclosure: Oragenics disclosed in its 2025 Annual Report that its independent auditor provided an unqualified opinion on its financial statements, yet included an explanatory paragraph regarding the company's ability to continue as a going concern, indicating financial uncertainty that may impact investor confidence.
- Financial Reporting Compliance: This announcement complies with NYSE American LLC Company Guide Section 610(b), emphasizing the company's commitment to financial transparency, even though there were no changes to the financial statements or the Annual Report.
- Clinical Development Progress: Oragenics' lead candidate, ONP-002, is in Phase IIa clinical development aimed at treating concussions and mild traumatic brain injuries affecting approximately 69 million people annually, showcasing the company's potential in the neuropharmaceutical sector.
- Future Outlook: The company is exploring ways to broaden its CNS pipeline strategy through both internal development and strategic business development, demonstrating a commitment to innovation and market expansion despite facing financial challenges.
See More
Oragenics Secures Clinical Trial Approval in Australia
- Clinical Trial Approval: Oragenics has received final approval from the Human Research Ethics Committee in Australia to commence its Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (mTBI), marking a significant advancement in developing the first pharmacological treatment for brain injuries.
- Significant Market Potential: The global market for mild traumatic brain injuries is projected to exceed $9 billion by 2030, and if approved by the FDA, ONP-002 would become the first pharmacological standard of care, addressing the needs of millions of patients currently without effective treatment options.
- Innovative Drug Mechanism: ONP-002 is designed as a first-in-class neurosteroid that targets the underlying biological mechanisms of brain injury by reducing neuroinflammation and oxidative stress, representing a potential paradigm shift from mere symptom management to active neurological intervention.
- Rigorous Trial Design: The Phase IIa clinical trial will enroll 40 patients to assess the drug's safety and tolerability, with data readout expected by the end of 2026; successful results will support further investigational new drug applications in the U.S.
See More
Oragenics Advances ONP-002 Clinical Trials for Concussion Treatment
- Clinical Trial Readiness: Oragenics has completed preparations for clinical trial sites in Australia, with the first patient dosing for ONP-002 expected to commence in 2026, marking a significant advancement in the field of brain therapeutics and potentially becoming the first pharmacological treatment for concussions.
- Significant Market Potential: The unique intranasal delivery system of ONP-002 is designed to rapidly deliver medication to the brain, targeting the approximately 1.7 to 3.8 million Americans who suffer from traumatic brain injuries annually, and if approved, it will enter a global concussion market projected to reach $9 billion by 2030.
- Strong Financial Backing: The company raised $16.5 million through the issuance of Series H convertible preferred stock and warrants, ensuring funding for the clinical development and operations of ONP-002, while a clean balance sheet with zero debt provides ample runway for future trials.
- Strategic Partnerships and Innovation: Oragenics has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for optimizing drug discovery, which may facilitate the expansion of its molecular portfolio and enhance the company's competitive edge in the neuroscience sector.
See More
